ClinicalTrials.gg
CompletedNCT05428943Updated Aug 10, 2026Results posted

OPT101 in Type 1 Diabetes Patients

A Phase 1 interventional study of OPT101 in Diabetes Mellitus, Type 1, sponsored by Op-T LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Op-T LLC · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
801st of 1,242
24 · median 40
Started
2022
with 61 others
Phase 1
147 of 1,458
11 open now
Registered
1,181st of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 801st largest by enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2022, is one of 147 in phase 1, and was the 1,181st registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.

Read the detailed description

This study is a randomized, multicenter, placebo-controlled, double blinded study that will be conducted as a multiple ascending doses (MAD) study to measure safety, the immunological, and the clinical effects of 1.1 and 2.8 mg/kg doses of OPT101 that were found to be safe in the OPT-100-30 (IND 150941) Phase 1a study performed in healthy volunteers.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give for the trial
  2. Male or female aged ≥18 years on the day of signing informed consent
  3. Diagnosis of Type 1 diabetes (T1D) within the last 20 years
  4. Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening
  5. Women of must have a negative highly sensitive serum test (beta-human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1 Day 1 prior to receiving the product.
  6. Women must agree to use one of the following methods of for the duration of the clinical trial: systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device.

    -

Exclusion criteria

Exclusion Criteria:

  1. Is over the age of 60 years old
  2. Currently has or had a history of
  3. Has an immune deficiency syndrome (for example, severe combined immunodeficiency syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic granulomatous disease), or bone marrow or organ transplantation, or a disease associated with lymphopenia
  4. Is currently receiving an immuno-modulatory treatment.
  5. Patients with a history of venous and arterial thromboembolic events including, but not limited to, the following: deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, , or arterial insufficiency causing digital gangrene should be excluded. In addition, patients with recent immobilization or recent surgery, should be excluded. Patients with a history of abnormal prothrombotic laboratories such as congenital or inherited deficiency of antithrombin III, protein C, protein S, or confirmed diagnosis of antiphospholipid syndrome should also be excluded.
  6. Has active infections, is prone to infections or has chronic, recurrent or opportunistic infectious disease, including but not limited to, Epstein-Barr virus (EBV), cytomegalovirus (CMV) chronic renal infection, chronic chest infection, sinusitis, recurrent urinary tract infection, Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis or an open, draining, or infected non-healing skin wound or ulcer
  7. Has recent or active hepatitis A infection, current/chronic and infection, or infection. Participants with immunity to hepatitis B from previous infection (defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody [anti-HBs]) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) may be eligible to participate.
  8. Has a history of latent or active TB
  9. Has received a live (attenuated) vaccine within the last 60 days, including patients who plan to receive live (attenuated) vaccines during the study or within 60 days after the final dose of study treatment.
  10. Patients with abnormal laboratory test values in screening blood samples. In particular patients with the following should be excluded:

    i. Patients with abnormal coagulation panel at screening such as abnormal PT or or fibrinogen ii. Abnormal liver function tests:

1. Liver enzyme abnormalities (except in the case of known Gilbert's syndrome) 2. or ALT ≥3x and total ≥2x ULN 3. AST or ALT ≥5x ULN 4. AST or ALT ≥3x ULN if associated with appearance or worsening of rash or hepatitis symptoms iii. Abnormal counts (\<150,000mcL or > 450,000mcL) iv. Abnormal white blood cell counts (\<3mL or > 11mL) v. Abnormal (\<50mg/dL or >1.10mg/dL) vi. Abnormal Factor VIII (> 160%) vii. Abnormal D-Dimer (> 500ng/mL FEU) 11. Patients planning to undergo elective procedures or surgeries at any time after signing the ICF through the follow-up visit.

12. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.

13. Recent history of bleeding or bleeding disorders or any condition whereby in the opinion of the treating investigator giving anti-coagulation during treatment would be .

14. History of to antihistamines. 15. Weight is over 250lbs. 16. Patients with active drug or alcohol abuse within 1 year prior to screening 17. Patient is participating in a clinical trial of another drug or device, including patients who have participated in another study for a duration of 5 half-lives of the investigational agent.

18. Patient is a prisoner 19. Investigators could exclude patients with any medical condition, including, but not limited to, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or a psychiatric condition that, in the opinion of the Investigator, could compromise the participant's ability to participate in this study.

-

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Other
    OPT101 1.1 mg/kg and Placebo

    9 subjects (6 investigational product:3 placebo)

    Drug: OPT101

  • Other
    OPT101 2.8 mg/kg and Placebo

    9 subjects (6 investigational product:3 placebo)

    Drug: OPT101

Interventions

  • DrugOPT101

    15-mer peptide derived from the sequence of mouse CD154.

06

What researchers measure

Primary outcomes

  1. Number of Treatment-related AE's as Assessed by CTCAE v4.0

    Number of treatment-related adverse events as assessed by CTCAE v4.0 over 42 days for all participants.

    Time frame: 42 days

Secondary outcomes

  1. Serum Samples Collected to Determine AUC0-t

    Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)

    Time frame: 42 days

  2. Serum Samples Collected to Determine Cmax

    Blood samples will be collected to determine the serum Cmax levels of OPT101 (pg/mL)

    Time frame: 42 Days

  3. Serum Samples Collected to Determine CL/F

    Blood samples will be collected to determine the CL/F values of OPT101 (mL/min/kg)

    Time frame: 42 days

  4. Serum Samples Collected to Determine t1/2

    Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)

    Time frame: 42 days

  5. Serum Samples Collected to Determine HbA1C From Baseline Pre Mixed Meal Tolerance Test to Day 56 Pre Mixed Meal Tolerance

    Serum samples collected to determine HbA1C levels from baseline pre mixed meal tolerance to Day 56 pre mixed meal tolerance test of OPT101 (mmol/mole)

    Time frame: 56 days

  6. Serum Samples Collected to Determine C-peptide Post Mixed Meal Tolerance Test

    Serum samples collected to determine C-Peptide values (ng/mL), post mixed-meal tolerance for End of Study (EOS).

    Time frame: 42 days

  7. Serum Samples Collected to Determine Glucose Levels Post Mixed Meal Tolerance Test at End-of-Study

    Serum samples collected to determine glucose levels (mmol/L) post mixed meal tolerance test at End-of-Study

    Time frame: 42 days

07

Results

Posted Aug 10, 2026

Participant flow

Able and willing and able to give informed consent for the trial Male or female aged ≥18 years on the day of signing informed consent Diagnosis of T1D within the last 20 years Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening Women of childbearing potential must have a negative highly sensitive serum test (beta- human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1

Participant flow — Overall Study
Milestone1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Started888
Completed666
Not completed222

Outcome measures

SecondarySerum Samples Collected to Determine AUC0-t

Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)

Time frame:
42 days
Reported as:
Mean · pg/mL*min
Serum Samples Collected to Determine AUC0-t
pg/mL*min1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Serum Samples Collected to Determine AUC0-t2197643 ± 14364051839862 ± 2443513NA ± NA
SecondarySerum Samples Collected to Determine Cmax

Blood samples will be collected to determine the serum Cmax levels of OPT101 (pg/mL)

Time frame:
42 Days
Reported as:
Mean · pg/mL
Serum Samples Collected to Determine Cmax
pg/mL1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Serum Samples Collected to Determine Cmax71333 ± 4775956764 ± 77354NA ± NA
PrimaryNumber of Treatment-related AE's as Assessed by CTCAE v4.0

Number of treatment-related adverse events as assessed by CTCAE v4.0 over 42 days for all participants.

Time frame:
42 days
Reported as:
Number · Adverse Events
Number of Treatment-related AE's as Assessed by CTCAE v4.0
Adverse Events1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Number of Treatment-related AE's as Assessed by CTCAE v4.0110
SecondarySerum Samples Collected to Determine CL/F

Blood samples will be collected to determine the CL/F values of OPT101 (mL/min/kg)

Time frame:
42 days
Reported as:
Mean · mL/min/kg
Serum Samples Collected to Determine CL/F
mL/min/kg1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Serum Samples Collected to Determine CL/F0.40 ± 0.143.84 ± 3.15NA ± NA
SecondarySerum Samples Collected to Determine t1/2

Blood samples will be collected to determine the serum concentrations of OPT101 (mg/kg)

Time frame:
42 days
Reported as:
Mean · minutes
Serum Samples Collected to Determine t1/2
minutes1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Serum Samples Collected to Determine t1/22.3 ± 0.92.0 ± 0.4NA ± NA
SecondarySerum Samples Collected to Determine HbA1C From Baseline Pre Mixed Meal Tolerance Test to Day 56 Pre Mixed Meal Tolerance

Serum samples collected to determine HbA1C levels from baseline pre mixed meal tolerance to Day 56 pre mixed meal tolerance test of OPT101 (mmol/mole)

Time frame:
56 days
Reported as:
Mean · mmol/mole
Serum Samples Collected to Determine HbA1C From Baseline Pre Mixed Meal Tolerance Test to Day 56 Pre Mixed Meal Tolerance
mmol/mole1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Serum Samples Collected to Determine HbA1C From Baseline Pre Mixed Meal Tolerance Test to Day 56 Pre Mixed Meal Tolerance0.53 ± 0.830.12 ± 0.480.06 ± 0.43
SecondarySerum Samples Collected to Determine C-peptide Post Mixed Meal Tolerance Test

Serum samples collected to determine C-Peptide values (ng/mL), post mixed-meal tolerance for End of Study (EOS).

Time frame:
42 days
Reported as:
Mean · ng/mL
Serum Samples Collected to Determine C-peptide Post Mixed Meal Tolerance Test
ng/mL1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Serum Samples Collected to Determine C-peptide Post Mixed Meal Tolerance Test0.03 ± 0.070.07 ± 0.260.16 ± 0.26
SecondarySerum Samples Collected to Determine Glucose Levels Post Mixed Meal Tolerance Test at End-of-Study

Serum samples collected to determine glucose levels (mmol/L) post mixed meal tolerance test at End-of-Study

Time frame:
42 days
Reported as:
Mean · mmol/L
Serum Samples Collected to Determine Glucose Levels Post Mixed Meal Tolerance Test at End-of-Study
mmol/L1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Serum Samples Collected to Determine Glucose Levels Post Mixed Meal Tolerance Test at End-of-Study0.53 ± 0.830.12 ± 0.480.06 ± 0.43

Adverse events

Collected over From enrollment until end of study, 42 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.1 mg/kg OPT1010/6 (0%)0/6 (0%)1/6 (16.7%)
2.8 mg/kg OPT1010/6 (0%)0/6 (0%)1/6 (16.7%)
Placebo OPT101-PTM0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent serious events
Most frequent serious events
Event1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
Infusion site extravasationSkin and subcutaneous tissue disorders0/60/60/8
Most frequent other events
Most frequent other events
Event1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTM
FatigueGeneral disorders1/61/60/8

Baseline characteristics

3 females received the 1.1 mg/kg dose, 3 and females received the 2.8 mg/kg dose. 3 males received the 1.1 mg/kg dose, and 3 males received the 2.8 mg/kg dose. 5 females and 3 males were administered placebo between the 2 cohorts included in the study.

Age, Customized
Age, Customized(Years)1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTMTotal
Mean Years28.8 ± 4.332.3 ± 10.232.0 ± 7.331.1 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTMTotal
Female33511
Male3339
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTMTotal
% White66618
% Hispanic or Latino2204
% Black or African American0011
% Asian, Native Hawaiian or Other Pacific Islander0011
Weight of Subject (kg)
Weight of Subject (kg)(kg)1.1 mg/kg OPT1012.8 mg/kg OPT101Placebo OPT101-PTMTotal
Mean74.0 (65.5 to 87.3)75.2 (49.0 to 93.1)79.3 (60.8 to 101.8)76.5 (49.0 to 101.8)
08

Study locations

2 sites
  • Diablo Clinical Research Center
    Walnut Creek, California 94598, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Feb 2024, 16 months.

Results were first posted in Aug 2026, 2 years 5 months after primary completion.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 16 months is above that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jun 23, 2022
StartActual
Sep 27, 2022
Primary completionActual
Feb 21, 2024
CompletionActual
Feb 21, 2024
Results first posted
Aug 10, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05428943
Lead sponsor
Op-T LLC
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Sep 27, 2022
Primary completion
Feb 21, 2024
Completion
Feb 21, 2024
Results posted
Aug 10, 2026
Last update
Aug 10, 2026

Study contacts

Lisa Boswell, MS
study director · OP-T

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OPT101

Start the discussion